Table 2.
Post‐index adherence and persistence outcomes at 12‐month follow‐up in propensity‐score‐matched cohort: Main analysis population
| Matched dulaglutide vs. liraglutide | Matched dulaglutide vs. exenatide once weekly | |||||
|---|---|---|---|---|---|---|
| Outcome variable | Dulaglutide n = 2427 | Liraglutide n = 2427 | P | Dulaglutide n = 1808 | Exenatide once weekly n = 1808 | P |
| Adherence | ||||||
| PDC (%), mean (SD) | 67.3 (32.06) | 59.5 (32.63) | <0.001 | 66.8 (32.24) | 51.3 (34.62) | <0.001 |
| PDC ≥0.80, n (%) | 1242 (51.2) | 927 (38.2) | <0.001 | 917 (50.7) | 576 (31.9) | <0.001 |
| Persistence | ||||||
| Days of persistent index GLP‐1RA use, mean (SD) | 252.8 (136.41) | 218.2 (143.85) | <0.001 | 251.4 (137.45) | 192.5 (140.22) | <0.001 |
| Patients who were persistent to index GLP‐1RA, n (%) | 1334 (55.0) | 1064 (43.8) | <0.001 | 992 (54.9) | 622 (34.4) | <0.001 |
Abbreviations: GLP‐1RA, glucagon‐like peptide receptor agonist; PDC, proportion of days covered.